

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/16, 16/10, A61K 39/21, 39/295, G01N 33/569</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/52040</b> <b>(43) International Publication Date:</b> 8 September 2000 (08.09.00)
<b>(21) International Application Number:</b> PCT/NO00/00075 <b>(22) International Filing Date:</b> 2 March 2000 (02.03.00) <b>(30) Priority Data:</b> 19991078 4 March 1999 (04.03.99) NO <b>(71) Applicant (for all designated States except US):</b> BIONOR A/S [NO/NO]; Strømdalsjordet 4, N-3705 Skien (NO). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> SÖRENSEN, Birger [NO/NO]; Meierlia 3, N-3727 Skien (NO). <b>(74) Agent:</b> BRYN & AARFLOT AS; P.O. Box 449 Sentrum, N-0104 Oslo (NO).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> HIV PEPTIDES, ANTIGENS, VACCINE COMPOSITIONS, IMMUNOASSAY KIT AND A METHOD OF DETECTING ANTIBODIES INDUCED BY HIV			
<b>(57) Abstract</b> <p>The present invention comprises novel and modified peptides capable of inducing an HIV-I specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.</p>			